Category «Uncategorized»

Maritupirdine

Maritupirdine CAS 1025725-91-0 MF C21H24N2 MW304.4 g/mol 2,3,4,5-TETRAHYDRO-2,8-DIMETHYL-5-PHENETHYL-1H-PYRIDO(4,3-B)INDOLE 2,8-dimethyl-5-(2-phenylethyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoleserotonin receptor antagonist, antidepressant, AVN-101, AVN 101, CD 008 0045, 6MHR5IV28S MARITUPIRDINE is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication. Maritupirdine (developmental code name AVN-101), a close structural analogue of latrepirdine, is a selective 5-HT6 receptor antagonist which is under development by Avineuro Pharmaceuticals for the treatment …

Luvometinib

Luvometinib CAS 2739690-43-6 MF C26H22F2IN5O4S MW665.5 g/mol CHINA 2025, APPROVALS 2025 N-[3-[6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodoanilino)-1-methyl-2,5-dioxopyrido[2,3-d]pyridazin-8-yl]phenyl]cyclopropanesulfonamide N-{3-[6-cyclopropyl-3-fluoro-4-(2-fluoro-4-iodoanilino)-1-methyl-2,5-dioxo-1,2,5,6-tetrahydropyrido[2,3-d]pyridazin-8-yl]phenyl}cyclopropanesulfonamidemitogen-activated protein kinase (MEK) inhibitor, antineoplastic, FCN 159, FCN-159, B2DYT4V89X Luvometinib is a drug for the treatment of various types of cancer. It is a selective, orally administered inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/MEK2), developed by Fosun Pharma for the treatment of rare malignancies, especially …

Lutetium (177Lu) tezuvotide tetraxetan

Lutetium (177Lu) tezuvotide tetraxetan CAS2613239-73-7 MF C60H92F177LuN12O23Si , 1573.5 g/mol 2-[4-[2-[[(2R)-1-[[(1R)-1-carboxy-5-[[4-[[(4R)-4-carboxy-4-[[(4S)-4-carboxy-4-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]butanoyl]amino]butyl]amino]-4-oxobutanoyl]amino]pentyl]amino]-3-[[4-[ditert-butyl(fluoro)silyl]benzoyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;lutetium-177(3+) antineoplastic, 177LU-RHPSMA-10.1, RHPSMA-10.1 LUTETIUM LU-177, FJ9Z7Y8MRW Lutetium (177Lu) tezuvotide tetraxetan ($^{177}$Lu-rhPSMA-10.1) is an experimental radioligand therapy, developed by Bracco, that targets prostate-specific membrane antigen (PSMA) to treat metastatic castration-resistant prostate cancer. It uses a radiohybrid (rh) PSMA molecule, designed to have high binding affinity to PSMA-positive cancer …

Lecufexor

Lecufexor CAS 2247972-61-6 MF C32H21Cl3N2O5 MW619.88 7-Benzoxazolecarboxylic acid, 5-[2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methoxy]phenyl]ethynyl]-2-cyclopropyl- 5-[2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]ethynyl]-2-cyclopropyl-1,3-benzoxazole-7-carboxylic acid farnesoid X receptor (FXR) agonist, K3K2F4N8BY, ID 119031166, ID 166 Lecufexor is a farnesoid X receptor (FXR) agonist. Lecufexor (also known as ID119031166 or ID166) is a potent, selective, and non-steroidal farnesoid X receptor (FXR) agonist. It is primarily studied for its potential in treating liver diseases, particularly Non-Alcoholic Steatohepatitis (NASH) and liver fibrosis. Key …

Laselipag

Laselipag CAS 475085-57-5 MF C25H29N3O3 MW 419.52 2-[4-[(5,6-diphenylpyrazin-2-yl)-propan-2-ylamino]butoxy]acetic acid {4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}acetic acidprostanoid receptor agonist, ACT-333679, ACT 333679, ACT333679, E9PC7N0DID, MRE 269 ACT-333679 is a member of the class of pyrazines that is {4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetic acid carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. The active metabolite of selexipag, an orphan drug used for the …

Laroprovstat

Laroprovstat CAS 2455427-91-3 MF C20H20F2N6O2 MW414.4 g/mol 1-[6-[[(1S,3S)-3-[[5-(difluoromethoxy)pyrimidin-2-yl]amino]cyclopentyl]amino]-3-pyridinyl]pyridin-2-one 6′-{[(1S,3S)-3-{[5-(difluoromethoxy)pyrimidin-2-yl]amino}cyclopentyl]amino}-2H-[1,3′-bipyridin]-2-oneproprotein convertase subtilisin/kexin type 9 (PCSK9), inhibitor, antihyperlipidaemic, 9EEL3YMY29, PCSK9-IN-12, AZD 0780, AZD-0780 SYN US11248001, PAT PAT AS ON OCT2025 4.511 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT join me on Linkedin Anthony Melvin Crasto Ph.D – India | LinkedIn join me on Researchgate RESEARCHGATE join me on Facebook …

Isomiosamine

Isomiosamine CAS 53844-46-5 MF C9H10N2 MW 146.19 g/mol 3-(3,4-dihydro-2H-pyrrol-2-yl)pyridine (+/-)-Isomyosmine rac-(3R)-3-(3,4-dihydro-2H-pyrrol-2-yl)pyridinetumor necrosis factor alpha (TNFα) inhibitor, MyMD-1, MYMD-1, Isomyosamine, 3A50Y1J4LP, MyMD Pharmaceuticals synthetic derivative of tobacco alkaloids Isomyosamine, also known as MyMD-1 or MYMD-1, is a synthetic derivative of tobacco plant alkaloids being developed as a metabolic- and immunomodulator by MyMD Pharmaceuticals. To date, isomyosamine has been shown to suppress …

Ismidenon

Ismidenon CAS 887603-94-3 MF C15H12N2O MW236.27 g/mol spiro(imidazo-(1,2-a)pyridine-3,2-indan)-2(3H)-one 1′,3′-dihydro-2H-spiro[imidazo[1,2-a]pyridine-3,2′-inden]-2-onevoltage-dependent T-type calcium channel modulator, ZSET 1446, ST 101, 7TTT61784C ST-101 is a small peptide antagonist of C/EBPβ and T-type calcium channel activator. ST101 has been used in trials studying the treatment of Essential Tremor and Alzheimer’s Disease. Ismidenon is an orally bioavailable azaindolizinone derivative and acetylcholine releasing agent, with potential neurocognitive-enhancing activity. …

Idrebormilast

Idrebormilast CAS 2415085-44-6 MF C18H22BNO4, MW 327.18 Pyridine, 3-[(4R)-2-hydroxy-1,2-oxaborolan-4-yl]-5-(4-methoxy-3-propoxyphenyl)- (4R)-4-[5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl]-1,2-oxaborolan-2-olphosphodiesterase 4 (PDE4) inhibitor, non-steroidal anti-inflammatory, M6ZU548FWD, PF07038124, PF 07038124 PF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo). IDREBORMILAST is a small molecule drug with a maximum clinical trial phase of II …

Gridegalutamide

Gridegalutamide CAS 2446929-86-6 MF C41H45F3N8O5S MW818.9 g/mol 2-[(2R)-4-[2-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]-2-ethylphenoxy]ethyl]-2-methylpiperazin-1-yl]-N-[3-[[(3R)-2,6-dioxopiperidin-3-yl]amino]phenyl]acetamide antiandrogen, antineoplastic, BMS 986365, CC 94676, BMS-986365, CC-94676, CEL 010355, VA228VR2DI, Gridegalutamide is an investigational oral androgen receptor (AR) degrader being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It belongs to a class of drugs called proteolysis targeting chimeras (PROTACs), which are designed to selectively degrade specific proteins by hijacking the ubiquitin-proteasome system.[1][2] CC-94676 …